Arena Pharmaceuticals, Inc. (ARNA) - Financial and Strategic SWOT Analysis Review by GlobalData

VIEWS: 19 PAGES: 44

More Info
									            Arena Pharmaceuticals, Inc. (ARNA) - Financial and Strategic SWOT
                                     Analysis Review
        Reference Code: GDPH66494FSA                                                                                          Publication Date: MAR 2013

          6154 Nancy Ridge Drive                             Phone              +1 858 4537200                  Revenue          27.6 (million USD)
          San Diego, CA                                      Fax                +1 858 4537210                  Net Profit       -109.22 (million USD)
          92121                                              Website            www.arenapharm.com              Employees        293
                                                                                                                                 Pharmaceuticals           &
          United States                                      Exchange           ARNA [NASDAQ]                   Industry
                                                                                                                                 Healthcare

       Company Overview
       Arena Pharmaceuticals, Inc., (Arena) is a development stage bio-pharmaceutical company. Primarily, the company is engaged in
       the research, development and commercialization of innovative novel therapies for the treatment of various diseases including
       obesity, diabetes, pulmonary arterial hypertension, thrombotic diseases, autoimmune diseases and pain management. Arena has
       only one product in its portfolio, lorcaserin HCl (brand name-BELVIQ), approved for marketing in the US, and indicated for chronic
       weight management. The other four products are in several clinical stages, namely, APD811, Temanogrel, APD334 and APD371
       and GPR119 receptor.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Arena Pharmaceuticals, Inc., SWOT Analysis
         Jack Lief                           Chairman                                 Strengths                              Weaknesses
         Dr. Dominic        P.    Behan, Chief Scientific Officer
                                                                                      Technology Base                        Lack of Product Based
         Ph.D.
                                                                                                                             Revenues
         Donald D. Belcher                   Director                                 Focused Research and
                                                                                      Development Activities                 Negative Profitability
         Scott H. Bice                       Director
         Dr. Tina S. Nova                    Director
        Source: Annual Report, Company Website, Primary and Secondary
                                                                                      Opportunities                          Threats
        Research, GlobalData
                                                                                      Market Potential: Obesity              Uncertain R&D Outcomes
       Share Data
                                                                                      Changing Demographics                  Stringent Government
         Arena Pharmaceuticals, Inc.
                                                                                                                             Regulations
        Share Price (USD) as on 15-Mar-                                  8.03
        2013
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        EPS (USD)                                                       -0.80        GlobalData
        Market Cap (million USD)                                       1,745
        Enterprise Value (million USD)                                 1,654
        Shares Outstanding (million)                                     217
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 04, 2013         Arena Pharma Reports Revenue Of $27.6m In
                                                                                                           2012
                                                                                      Nov 06, 2012         Arena Pharma Reports Revenue Of $1.5m In
                                                                                                           Q3 2012
                                                                                      Aug 09, 2012         Arena Pharma Reports Revenue Of $22m In
                                                                                                           Q2 2012
                                                                                      May 01, 2012         Arena Pharma Reports Revenue Of $2.2m In
                                                                                                           Q1 2012
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
                                                                                     GlobalData
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData




Arena Pharmaceuticals, Inc. (ARNA) - Financial and Strategic                                                                   Reference Code: GDPH66494FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Arena Pharmaceuticals, Inc. - Key Facts............................................................................................................................................ 5
       Arena Pharmaceuticals, Inc. - Key Employees................................................................................................................................... 6
       Arena Pharmaceuticals, Inc. - Key Employee Biographies ................................................................................................................ 7
       Arena Pharmaceuticals, Inc. - Major Products and Services .............................................................................................................. 8
       Arena Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data ............................................................................................. 9
          Arena Pharmaceuticals, Inc., Pipeline Products by Therapy Area .................................................................................................. 9
          Arena Pharmaceuticals, Inc., Pipeline Products by Development Phase ..................................................................................... 10
       Arena Pharmaceuticals, Inc. - History .............................................................................................................................................. 12
       Arena Pharmaceuticals, Inc. - Company Statement ......................................................................................................................... 14
       Arena Pharmaceuticals, Inc. - Locations And Subsidiaries .............................................................................................................. 20
          Head Office ................................................................................................................................................................................... 20
          Other Locations & Subsidiaries ..................................................................................................................................................... 20
       Section 2 – Company Analysis ......................................................................................................................................................... 21
       Arena Pharmaceuticals, Inc. - Business Description ........................................................................................................................ 21
       Arena Pharmaceuticals, Inc. - Corporate Strategy ........................................................................................................................... 22
       Arena Pharmaceuticals, Inc. - SWOT Analysis ................................................................................................................................ 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          Arena Pharmaceuticals, Inc. - Strengths....................................................................................................................................... 23
             Strength - Technology Base ...................................................................................................................................................... 23
             Strength - Focused Research and Development Activities ....................................................................................................... 23
             Strength - Strong Patent Portfolio ............................................................................................................................................. 23
          Arena Pharmaceuticals, Inc. - Weaknesses ................................................................................................................................. 24
             Weakness - Lack of Product Based Revenues ......................................................................................................................... 24
             Weakness - Negative Profitability .............................................................................................................................................. 24
          Arena Pharmaceuticals, Inc. - Opportunities................................................................................................................................. 24
             Opportunity - Market Potential: Obesity..................................................................................................................................... 24
             Opportunity - Changing Demographics ..................................................................................................................................... 24
          Arena Pharmaceuticals, Inc. - Threats .......................................................................................................................................... 25
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 25
             Threat - Stringent Government Regulations .............................................................................................................................. 25
             Threat - Intense Competition ..................................................................................................................................................... 25
       Arena Pharmaceuticals, Inc. - Key Competitors ............................................................................................................................... 26
       Section 3 – Company Financial Ratios ............................................................................................................................................. 27
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 27
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 27
       Performance Chart ........................................................................................................................................................................... 29
       Financial Performance...................................................................................................................................................................... 29
       Financial Ratios - Interim Ratios....................................................................................................................................................... 30
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 31
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 32
          Arena Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 ............................................... 32


Arena Pharmaceuticals, Inc. (ARNA) - Financial and Strategic                                                                                                   Reference Code: GDPH66494FSA
SWOT Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
          Arena Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 ............................................... 33
       Arena Pharmaceuticals, Inc., Recent Deals Summary ..................................................................................................................... 34
       Section 5 – Company’s Recent Developments ................................................................................................................................ 35
          Arena Pharmaceuticals, Inc., Recent Developments .................................................................................................................... 35
             Mar 04, 2013: Arena Pharma Reports Revenue Of $27.6m In 2012 ......................................................................................... 35
             Nov 06, 2012: Arena Pharma Reports Revenue Of $1.5m In Q3 2012 ..................................................................................... 37
             Aug 09, 2012: Arena Pharma Reports Revenue Of $22m In Q2 2012 ...................................................................................... 38
             May 01, 2012: Arena Pharma Reports Revenue Of $2.2m In Q1 2012 .................................................................................... 38
             Mar 14, 2012: Arena Pharma Reports Revenue Of $2.1m In Q4 2011 ..................................................................................... 39
       Section 6 – Appendix ....................................................................................................................................................................... 40
          Methodology ................................................................................................................................................................................. 40
          Ratio Definitions ............................................................................................................................................................................ 40
          About GlobalData ....................
								
To top